CClinicalTrials.gg
CompletedNCT04704128SESAMEUpdated Jul 7, 2021

Identification of Pathophysiological Pathways and Therapeutic Targets in Primary Stomatodynia by Salivary Metabolomics

An observational study in Primary Burning Mouth Syndrome, sponsored by University Hospital, Tours. Completed at 1 site in France. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-07-07.

Sponsored by University Hospital, Tours · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
53
Ages
18 Years and older
Sex
Female
01

Study summary

Burning mouth syndrome (BMS) is defined by a chronic oral pain affecting especially postmenopausal women. Its physiopathology is still unknown and several hypotheses have been put forward to explain this syndrome, such as neurological, hormonal or inflammatory process. The recent development of salivary metabolomic profiling in oral diseases has led to the identification of potential pathways in such disorders. The aim of this study is to analyze the salivary metabolomic in BMS patients compared to healthy controls.

Read the detailed description

Burning mouth syndrome (BMS) is defined by a chronic oral pain affecting especially postmenopausal women. Its physiopathology is still unknown and several hypotheses have been put forward to explain this syndrome, such as neurological, hormonal or inflammatory process. The recent development of salivary metabolomic profiling in oral diseases has led to the identification of potential pathways in such disorders. The aim of this study is to analyze the salivary metabolomic in BMS patients compared to healthy controls.

02

Conditions studied

  • Primary Burning Mouth Syndrome

Keywords

  • Primary Burning Mouth Syndrome
  • Salivary metabolomic
03

In context

Burning Mouth Syndrome

44 studies on the registry are indexed under Burning Mouth Syndrome; 6 are open to participants now.

Browse Burning Mouth Syndrome studies →

Lead sponsor

University Hospital, Tours is the lead sponsor of 304 studies on the registry; 78 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Regarding the high predominance of this pathology among women and in order to optimize the study homogeneity, only women will be enrolled in this study.

In the control group, patients will be selected for having close characteristics with cases (pairing for age +/- 5 years and for sex).

Inclusion criteria

  • For cases : primary Burning Mouth Syndrome, based on the IHS diagnosis criteria
  • For cases : being able to realise the salivary collection
  • For controls : no primary BMS
  • For controls : being able to realise the salivary collection

Exclusion criteria

Exclusion Criteria for both groups:

  • Treatment by antibiotics in the previous month
  • New treatment in the previous two weeks
  • Active smoking
  • Active infectious or inflammatory oral disease
  • Systemic disease that could have an impact on the salivary metabolome or on the neurological system
  • Being under legal guardianship
  • Opposition to the processing of personal data
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
53 participants (actual)
Patient registry
No

Groups and cohorts

  • Case group

    women with primary stomatodynia

    Other: Salivic sample

  • Control group

    women without oral disease

    Other: Salivic sample

Interventions

  • OtherSalivic sample

    Collection of total saliva not stimulated

06

What researchers measure

Primary outcomes

  1. Comparative analysis of salivary metabolomic profiles between cases (primary BMS) and controls

    metabolites will be measured in saliva by chromatography-mass spectrometry

    Time frame: at inclusion

Secondary outcomes

  1. Comparative analysis of salivary neuropeptides between cases (primary BMS) and controls

    quantitative assessment of levels of neuropeptides (NGF, histamine, tryptase, kallicrein) will be assessed in saliva in cases and controls

    Time frame: at inclusion

  2. Comparative analysis of salivary hormones between cases (primary BMS) and controls

    quantitative assessment of levels of steroid hormones (cortisol, 11-desoxycortisol, DHEA, SDHEA, progesterone, 17-hydroxyprogesterone, testosterone, androstenedione) will be assessed in saliva in cases and controls

    Time frame: at inclusion

  3. Comparative analysis of salivary inflammatory cytokines between cases (primary BMS) and controls

    quantitative assessment of levels of cytokines (IL-2, IL-6, IL-18, TNFα) will be assessed in saliva in cases and controls

    Time frame: at inclusion

  4. Correlation between salivary biomarkers and pain characteristics

    metabolites profile, salivary neuropeptides, hormones and cytokines will be compared according to the category of pain (type I-II-III, neuropathic pain score DN4\>4)

    Time frame: at inclusion

07

Study locations

1 site
  • Department of Dermatology, Hospital University of Tours
    Tours, 37044, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 7, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04704128
Lead sponsor
University Hospital, Tours
Responsible party
Sponsor
First posted
Jan 11, 2021
Start date
Mar 10, 2021
Primary completion
May 12, 2021
Completion
May 12, 2021
Last update
Jul 7, 2021

Study contacts

Mahtab SAMIMI, MD-PhD
principal investigator · University Hospital, Tours

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion